$1,500
total
12 months
Duration
14
Total Visits
213
Spots Remaining
About This Study
This clinical trial is evaluating a new once-weekly injectable medication for adults with Type 2 Diabetes. The study aims to determine if this treatment can better control blood sugar levels compared to current standard treatments.
Study Objectives
To evaluate the efficacy and safety of the investigational drug in reducing HbA1c levels over 52 weeks.
Eligibility Requirements
Inclusion Criteria
- Adults 18-65 years old
- Diagnosed with Type 2 Diabetes for at least 1 year
- Currently taking oral diabetes medication
- HbA1c between 7.0% and 10.0%
- BMI between 25 and 40
Exclusion Criteria
- Pregnant or nursing women
- History of diabetic ketoacidosis
- Severe kidney disease
- Current insulin use
Frequently Asked Questions
Study Location
Massachusetts General Hospital
Boston, MA 02115
Map View
Research Team
Dr. Sarah Chen
Harvard Medical School
Clinical Trials Office
Study Timeline
Start DateMarch 1, 2024
End DateDecember 31, 2025
Enrollment287 / 500